An Investigational Scan (18F-DCFPyL PET/CT) in Detecting Progression in Patients with Metastatic or Non-metastatic Castration Resistant Prostate Cancer Receiving Standard Androgen Receptor Targeted Treatment

Inclusion Criteria

• Histological confirmation of prostate cancer
• Patients receiving androgen deprivation treatment (ADT) with gonadotrophin releasing hormone (GnRH) analogs, GnRH antagonists or bilateral orchiectomy of any duration
• Cohort A: nmCRPC (Status post [S/P] primary treatment with radical prostatectomy, radiation of any type or both) * Negative 99mTc-methylene diphosphonate bone scan and CT of the chest abdomen and pelvis within 6 weeks of 18F-DCFPyL PET/CT * Treatment with ADT with or without a second line novel androgen receptor (AR) targeted treatment (abiraterone, enzalutamide, or both) or 4 weeks after discontinuation of first generation antiandrogen (bicalutamide , flutamide, nilutamide- one or more permitted) for >= 12 months * Rising PSA >= 10 ng/ml (confirmed by 2 determinations one week apart) * PSA doubling time (PSADT) =< 9 months
• Cohort B: mCRPC * Treatment with ADT with or without abiraterone and or enzalutamide or both for >= 6 months and/or 4 weeks after discontinuation of first generation antiandrogen (bicalutamide , flutamide, nilutamide- one or more permitted) * PSA >= 2.0 ng/ml confirmed X 1 week apart, any PSADT
• Patients enrolled in other clinical trials are eligible if they satisfy all other criteria of eligibility
• No new therapeutic interventions planned or scheduled to be instituted prior to the course of this study both on cohorts A and B before conventional radiologic progression is evidenced
• Patients or their legal representatives must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures

Exclusion Criteria

• Patients will be excluded from enrollment if he had a radioisotope within 5 physical half-lives prior to PET imaging